{"schema_version":"1","generated_at":"2026-11-21T12:22:02.216Z","data_as_of":null,"url":"https://www.findmykol.com/kol/joshua-mcfarlane","json_url":"https://www.findmykol.com/kol/joshua-mcfarlane/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"joshua-mcfarlane","name":"Joshua McFarlane","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Virginia Cancer Institute","institution_url":"https://www.findmykol.com/institution/virginia-cancer-institute","city":"Richmond","state":"VA","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Joshua McFarlane is an Oncology physician affiliated with Virginia Cancer Institute. OpenAlex indexes 11 publications with 444 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":11,"cited_by_count":444,"h_index":7,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":57,"program_years":{"first":2021,"last":null},"rows_total":128,"shown":3,"withheld":125,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":224.68,"payment_count":9},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":208.76,"payment_count":8},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":177.42,"payment_count":8}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":62.6,"classes_total":13,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":45.9,"drugs":[{"name":"Pembrolizumab","share_pct":59.7},{"name":"Nivolumab","share_pct":40.3}],"max_beneficiaries":27},{"class":"CD38-directed Cytolytic Antibody","setting":"administered","share_pct":12.1,"drugs":[{"name":"Daratumumab","share_pct":100}],"max_beneficiaries":13}]},{"area":"Musculoskeletal","share_pct":17,"classes_total":2,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":16.8,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":46},{"class":"Bisphosphonate","setting":"administered","share_pct":0.2,"drugs":[{"name":"Zoledronic acid","share_pct":100}],"max_beneficiaries":15}]},{"area":"Blood & clotting","share_pct":5.5,"classes_total":3,"classes":[{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":5.1,"drugs":[{"name":"Epoetin alfa","share_pct":100}],"max_beneficiaries":35},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":0.3,"drugs":[{"name":"Eliquis","share_pct":71.8},{"name":"Xarelto","share_pct":28.2}],"max_beneficiaries":22}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.6,"facility_pct":0.4},"source":"medicare"},"publications":{"total":11,"shown":5,"withheld":6,"matched_by":"OpenAlex author record","recent":[{"title":"P10.14 ctDNA and Real-World Response (rwR) in Patients With Lung Cancer From A Prospective Real-World Clinico-Genomic (PCG) Study","year":2021,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2021.08.319","status":"verified"},{"title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"journal":"Clinical Genitourinary Cancer","source_url":"https://doi.org/10.1016/j.clgc.2020.05.006","status":"verified"},{"title":"Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"journal":"Clinical Genitourinary Cancer","source_url":"https://doi.org/10.1016/j.clgc.2020.06.002","status":"verified"},{"title":"Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2019.37.7_suppl.562","status":"verified"},{"title":"A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer","year":2017,"journal":"The Oncologist","source_url":"https://doi.org/10.1634/theoncologist.2016-0223","status":"verified"}],"source":"works"},"similar":[{"name":"James Khatcheressian","slug":"james-khatcheressian","institution":"Virginia Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/james-khatcheressian","json_url":"https://www.findmykol.com/kol/james-khatcheressian/profile.json"},{"name":"Maurice Schwarz","slug":"maurice-schwarz","institution":"Virginia Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/maurice-schwarz","json_url":"https://www.findmykol.com/kol/maurice-schwarz/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":125,"publications":6}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}